i4 Competition Teams
CUALLI
Osvaldo Linares Gutiérrez
Alex Li
Chinmay Singh
KAIRS
Samanyu Dixit
Chinmay Singh
Hieu Doan
Sahaj Sapovadia
AVATAR
Davis Walker
Lewis Russell
Keira Berkawia
CorSentra
Vedika Venkataramanan
Abirami Senthil-Murugan
Talal Aslam
a
Cualli is developing a programmable probiotic platform that transforms microbes into "living medicines" designed to sequester environmental toxins, treat complex diseases and solve complex public health challenges
KAIRS is developing a smart, wearable rehabilitation sleeve for patients recovering from major knee surgeries, such as ligament repairs or total joint replacements. Following surgery, patients often experience an inhibited range of motion and struggle to adhere to at-home exercises without objective guidance. By integrating precise inertial sensors with machine learning models, the sleeve provides real-time biometric tracking and personalized feedback. This affordable solution complements expensive clinical equipment with a remote, clinician-supervised platform, ensuring consistent recovery progress and helping patients effectively restore joint function and independence.
A recent study on manual bag-valve-mask (BVM) ventilation effectiveness found that just 1% of paramedics met the European Resuscitation Council guidelines (10 breaths/minute, 6–8 mL/kg). Automated Ventilation Assist Technology for Active Resuscitation (AVATAR) aims to address manual ventilation inconsistencies in EMS settings. The pump and its frame attach directly to the BVM and the patient, delivering hands-free ventilation at a consistent rate and tidal volume. Currently, hospital-grade ventilators and other bulky, automated ventilation machines exist but aren't practical for EMS due to size or training requirements. AVATAR bridges this gap with accurate, reliable ventilation in a device designed specifically for EMS.
Type II diabetes affects 37 million Americans, increasing risk of sudden cardiac death 6.5-fold. Exercise, while the primary clinical recommendation for disease management, compounds this risk by unmasking silent arrhythmias. Current wearables fail: smartwatches lose AFib detection during motion; clinical patches reject exercise data as artifact. This gap leaves millions unmonitored at their moment of highest cardiac risk. CorSentra detects arrhythmia precursors during exercise, triggering full EKG capture with real-time alerts to enable life-saving intervention. Targeting a $16.5B market, CorSentra delivers the first exercise-validated monitoring solution for diabetics, providing data to detect and respond to fatal cardiac events.